TargetMol

NS 11

Product Code:
 
TAR-T33734
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T33734-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
NS 11 is an RGD-nonpeptidic mimetic.
CAS:
150044-75-0
Formula:
C14H25N5O4
Molecular Weight:
327.385
Purity:
0.98
SMILES:
NC(=N)NCCCC(=O)N1CCCC(C1)C(=O)NCCC(O)=O

References

Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban Shaker A Mousa, Jeffrey M Bozarth, Ulhas P Naik, Andrew Slee Br J Pharmacol. 2001 Jun; 133(3): 331?336. doi: 10.1038/sj.bjp.0703943 PMCID: PMC1572788 Pharmacological inhibition of ?3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity Ashley Browne, Laura A. Tookman, Carin K. Ingemarsdotter, Russell D. Bouwman, Katrina Pirlo, Yaohe Wang, Iain A. McNeish, Michelle Lockley Cancer Res. Author manuscript; available in PMC 2016 Jan 15.Published in final edited form as: Cancer Res. 2015 Jul 15; 75(14): 2811?2821. Published online 2015 May 14. doi: 10.1158/0008-5472.CAN-14-3761 PMCID: PMC4506788 Lymphocyte Adhesion to Candida albicans Christopher B. Forsyth, Herbert L. Mathews Infect Immun. 2002 Feb; 70(2): 517?527. doi: 10.1128/IAI.70.2.517-527.2002 PMCID: PMC127679 Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of ?IIb/?3 integrin Daniel W. Bougie, Mark Rasmussen, Jieqing Zhu, Richard H. Aster Blood. 2012 Jun 28; 119(26): 6317?6325. Prepublished online 2012 Apr 6. doi: 10.1182/blood-2012-01-406322 PMCID: PMC3383197